Max Hodak co-founded Neuralink with Elon Musk. Then he left and started Science Corporation. Last month, Science Corp closed a $230 million Series C at a $1.5 billion valuation. This week, Dr. Murat Gunel, chair of Yale Medical School’s Department of Neurosurgery, signed on as a scientific advisor with a singular goal: place the first Science Corp sensor in a human brain.

This is not a startup story. This is the opening act of human cognitive expansion.

What Is Happening Right Now

Neuralink has patients at home. A patient with ALS used the Neuralink N1 implant to control a motorized camera independently. Neuralink expanded its PRIME study to the UK, with the first UK patient controlling a computer within hours of surgery.

Paradromics received FDA approval for its Connexus BCI system to begin the Connect-One study, targeting speech restoration for patients with severe paralysis.

And Science Corp, Hodak’s new company, has its most advanced current product in the market already. PRIMA is a device the size of a grain of rice, implanted in the retina, that restores vision in patients with macular degeneration. It is in clinical trials with plans for European regulatory approval.

But PRIMA is the proof of concept. Hodak’s stated vision is larger: create reliable communication links between computers and the human brain, treating disease first and then enabling human enhancement, including the addition of entirely new senses.

The AI Integration Layer

This is where the genomics economy intersects with what most people still call the AI economy.

Brain-computer interfaces read neural signals. Those signals require AI to decode. The edge computing AI inside Neuralink’s implant processes raw neural activity through neural networks in real time, reducing latency and preserving privacy.

The AI does not just translate signals. It learns. It adapts to the individual. It becomes, over time, calibrated to a specific brain.

This is AI-assisted humanity. Not in a metaphorical sense. In a literal, surgical, millimeter-by-millimeter sense.

[NYSE:NVDA] Nvidia’s chips power the edge AI decoding inside next-generation implants. The computational demand for BCI-scale neural decoding is a direct driver of the same AI hardware stack that powers large language models.

The Investment Landscape

Science Corp (private): $230M Series C, $1.5B valuation. Not yet public. Neuralink (private): Ongoing trials. Not public. Backed by Elon Musk. Synchron (private): Also in trials for paralysis patients.

The public exposure to this space runs through the enabling infrastructure:

[NASDAQ:NVDA] Nvidia: edge AI for neural decoding. [NASDAQ:ISRG] Intuitive Surgical: precision robotic surgery, directly relevant to BCI implantation at scale. [NYSE:MDT] Medtronic: the largest implantable neurostimulator company in the world, already commercially deploying brain implants for Parkinson’s and pain.

Medtronic’s existing neurostimulation business, with thousands of implants in patients today, is the closest public analog to what Neuralink is building.

What This Means

The brain-computer interface field is moving from single digits to dozens of patients in clinical trials. Investor interest, in the words of one analysis this year, is sky-high.

The near-term applications are medical: ALS, paralysis, blindness, mental health. But the technology roadmap does not stop at disability. Hodak has said explicitly that Science Corp exists to create “reliable communication links between computers and the human brain” as a path toward enhancement, including adding new senses to the body.

That is not a healthcare claim. That is an infrastructure claim.

The human brain is the last unmonetized interface. The companies that solve the hardware, the AI decoding layer, and the regulatory pathway will have access to the most intimate and highest-value data in the genomics economy: the live activity of a human mind.

Sources: TechCrunch, STAT News, Nature, ScienceDaily, Applying AI

Genomics is currently being heavily utilized by the U.S. military across multiple domains, spanning soldier health, operational readiness, and long-term strategic planning. As genomic technologies mature, the Department of Defense (DoD) has increasingly treated them not only as medical tools, but as strategic assets capable of reshaping force sustainability, logistics, and national security economics.

One of the most immediate applications of genomics within the military is in enhancing medical outcomes for service members. Through agencies such as DARPA and the Defense Health Agency, the military funds research aimed at improving recovery time, resilience, and survivability in extreme environments. These efforts are often framed under DARPA’s guiding biomedical goals: “Optimize, Prevent, and Restore.” A notable example is DARPA’s Smart Red Blood Cells (RBCs) program, which sought to bioengineer human red blood cells to perform enhanced immune and sensing functions. The premise of the program was to create cells capable of responding dynamically to infection or injury, enabling faster recovery and improved battlefield survival (DARPA grant page).

From an economic perspective, programs like Smart RBCs illustrate how defense-funded genomics research subsidizes high-risk innovation that might otherwise be too costly for the private sector. The infrastructure, expertise, and intellectual property generated through these initiatives frequently spill over into civilian biotechnology, accelerating commercial advances in regenerative medicine, synthetic biology, and advanced therapeutics. Defense contracts often serve as early, non-dilutive funding sources for academic labs and biotech startups, reducing R&D risk and catalyzing private investment. In this way, military genomics programs do not exist in isolation; they help shape the broader biotech economy by seeding technologies that later enter healthcare markets.

At the same time, the military’s interest in genomics extends beyond defensive medicine into strategic threat assessment, particularly concerning gene editing technologies such as CRISPR-Cas systems. Although much of the discussion remains speculative, CRISPR has been formally identified as a potential national security concern due to its accessibility, scalability, and dual-use nature. In 2016, then–Director of National Intelligence James Clapper included gene editing technologies in the U.S. Intelligence Community’s Worldwide Threat Assessment, citing their potential for misuse in creating novel biological threats .

In response to these concerns, DARPA and other defense organizations have invested in biosecurity and counter-biotechnology programs, aimed at detection, attribution, and mitigation rather than offensive development. These efforts include early-warning biosurveillance systems, rapid vaccine platforms, and tools to identify genetically engineered organisms. Economically, this has fueled a growing biosecurity market, where companies develop diagnostics, sequencing platforms, and AI-driven surveillance tools that serve both military and civilian public health needs. The COVID-19 pandemic further reinforced the value of these systems, accelerating government procurement and long-term contracts that blur the line between defense and healthcare infrastructure.

Beyond direct threats to human health, genomics introduces the possibility of agricultural and ecological warfare, an area of increasing concern among security analysts. Rather than targeting populations directly, adversaries could hypothetically engineer pathogens or pests aimed at specific crops or keystone species. Such an approach could destabilize food supplies, disrupt trade, and induce economic collapse without immediate military confrontation. For example, targeted attacks on staple crops like wheat, rice, or corn—or on pollinators critical to agricultural productivity—could have cascading effects across global supply chains.

DARPA Release video

The economic implications of such a threat are profound. Agriculture is deeply intertwined with national security, employment, and geopolitical stability. A successful attack on a major crop system could inflate food prices, strain international trade relationships, and force governments to divert massive resources toward mitigation and recovery. As a result, military genomics increasingly overlaps with agricultural biotechnology, prompting investments in genetically resilient crops, pathogen-resistant livestock, and genomic monitoring of ecosystems. These efforts again stimulate commercial innovation, benefiting agritech firms while simultaneously raising ethical and regulatory questions about data ownership, genetic modification, and environmental risk.

Economic Implications: Defense Procurement and Venture Capital

The intersection of military genomics and economics is especially visible in venture capital flows and defense procurement strategies:

• Defense Procurement as Innovation Seed Funding. DoD programs often operate like venture investors for emerging biotech. Agencies such as DARPA, the Army Medical Research and Development Command, and the Air Force Office of Scientific Research issue Broad Agency Announcements (BAAs) that attract academic labs and commercial startups, fostering dual-use technologies spanning synthetic biology, genomic sequencing, and bioengineering. These procurements can validate early-stage firms, making them more attractive to institutional VC investors (NSF Interagency Synthetic Biology Working Group (SBWG)).
  
  

• Venture Capital and Commercial Spillover. Venture capital in genomics and life sciences has surged over the past decade, driven by breakthroughs in CRISPR, gene therapy, and high-throughput sequencing. According to market analyses, investments in genomics and synthetic biology startups have become a significant segment of life science venture capital, with companies developing tools such as sequencing platforms, bioinformatics software, and gene editing delivery systems drawing substantial funds. This VC ecosystem benefits indirectly from defense procurement, as military-funded breakthroughs de-risk technologies that later enter broad commercial markets, “the Defense Innovation Unit, a strategic sourcing organization for DoD, showed that for every $1 of prototype contract value awarded to a company, venture capitalists invest 10-20 times that amount in additional equity capital” (Mike Brown, Forbes). This illustrates how military investment de-risks technology investments and attracts commercial capital.

The economics of genomics is thus shaped by a feedback loop: government investment in strategic genomic R&D reduces technological uncertainty, attracting private capital and driving job creation, intellectual property formation, and downstream commercial products. In turn, a vibrant commercial genomics industry strengthens supply chains and expands the pool of technologies available for defense uses.

In sum, genomics occupies a uniquely dual-use position within the modern military ecosystem. It functions simultaneously as a tool for protecting soldiers, a domain of emerging security threats, and a powerful economic driver shaping biotechnology, healthcare, and agriculture. Defense investment in genomics lowers innovation barriers, accelerates commercialization, and influences market priorities, while also demanding new governance frameworks to manage risk, misuse, and long-term societal impact. As genomic technologies continue to advance, policymakers will face the challenge of balancing military preparedness and economic growth with ethical restraint and global stability.

Expanding the Boundaries of Human Capability

The Enhanced Humanity Opportunity

Enhanced Humanity is a core GMG category because it marks the moment genomics moves beyond treating disease and into deliberately expanding human capability, resilience, and longevity. This is where genomics stops functioning solely as a healthcare tool and begins operating as a forward-looking system for human potential.

The distinction matters.

Personalized medicine uses genomics to reduce risk, detect disease earlier, and optimize treatment—keeping people healthier within today’s biological limits.

Enhanced Humanity goes further.

It asks how genomics can extend those limits altogether: improving healthspan, cognitive and physical performance, stress tolerance, and long-term resilience in ways previously inaccessible. This includes longevity genomics, epigenetic reprogramming, metabolic optimization, cognitive enhancement, microbiome engineering, and genomic approaches to environmental stress resistance. Some applications are already commercial. Others are emerging. What unites them is intent: not just fixing what’s broken, but expanding what’s possible.

Imagine 2035

It’s 2035, and aging is no longer treated as an uncontrollable decline.

Your annual health review begins with a genomic and epigenomic assessment that tracks biological age across immune, metabolic, and neurological systems. AI models compare your data against longitudinal cohorts, detecting divergence long before disease manifests.

Your liver appears biologically younger than your chronological age. Your immune system does not. The response is immediate and targeted: gene-expression modulation, a senescence-reducing intervention validated through years of trials, and a microbiome recalibration tailored to your metabolic profile.

Cognitive fatigue follows a similar path. Your neurogenomic signature reveals stress sensitivity in specific pathways. Precision interventions—sleep-cycle optimization, metabolic support, cognitive training—are deployed. Performance rebounds measurably.

Health is no longer episodic. It is continuously tuned. Employers and self-insured systems underwrite projected healthspan, not actuarial averages. Prevention outperforms treatment economically. Longevity becomes measurable, improvable, and directly tied to productivity. Every component of this system exists today in isolation. By 2035, they are integrated.

How Enhanced Humanity Differs from Personalized Medicine

Personalized medicine asks how DNA can be used to keep an individual healthy. Enhanced Humanity asks how DNA can be used to expand what a human can do.

The same tools—sequencing, polygenic risk scores, multi-omics, AI—power both categories. The difference is intent and time horizon. Enhanced Humanity focuses on resilience beyond disease prevention: resistance to chronic stress, metabolic extremes, cognitive load, environmental disruption, and eventually non-terrestrial conditions.

Space exploration provides the clearest evidence that unmodified human biology has hard limits. Research from NASA and international space agencies shows that long-duration missions expose vulnerabilities that cannot be solved with conventional medicine alone—radiation-driven DNA damage, rapid bone and muscle loss, immune system dysregulation, microbiome disruption, and cognitive stress under prolonged isolation. These conditions act as a biological stress test, revealing where human physiology fails fastest. Genomic interventions developed for space translate directly to Earth-based applications, from aging populations to high-stress occupations and extreme environments. Space is not a niche use case; it is the most accelerated proving ground for Enhanced Humanity.

How GMG Covers Enhanced Humanity

GMG approaches Enhanced Humanity through a business and systems lens, not futurism or lifestyle optimization. Coverage focuses on where longevity and performance genomics become scalable platforms with recurring revenue models; how genomic data converts into subscription services, employer-funded programs, and payer-aligned offerings; regulatory boundaries between therapy, prevention, and enhancement; capital flows and adoption curves; and separating validated science from speculative hype. GMG aggregates scientific insight, then adds the economic and strategic layer leaders need to act.

Applications Already in Market

Enhanced Humanity is already taking shape through polygenic risk scoring for disease susceptibility and resilience; epigenetic clocks measuring biological age and intervention response; longevity diagnostics tracking inflammation, mitochondrial health, and metabolism; microbiome-based therapies affecting immunity, mood, and performance; wearables integrated with genetic risk models; and FDA-approved gerotherapeutics such as SGLT2 inhibitors, metformin, bisphosphonates, and GLP-1 agonists showing mortality reduction across age-related diseases. Research into senolytics, partial cellular reprogramming, and metabolic gene targets continues to accelerate, supported by rising private capital.

Market Outlook

Longevity and human optimization are converging into a major economic category. Global longevity and anti-aging markets are projected to exceed $180B by the mid-2030s, with 8–12% CAGR across therapeutics, diagnostics, consumer health, and wellness platforms. Precision health platforms continue double-digit growth as employers and consumers demand predictive, not reactive, systems. Capital is shifting upstream from treatment to optimization, representing a structural reallocation of healthcare spend comparable to the digital transformation of finance and media.

This shift is accelerated by falling sequencing and multi-omics costs, AI-driven risk and performance modeling, cultural demand for self-directed health control, employer incentives tied to productivity and longevity, convergence of wearables, biomarkers, and genomics, and clearer regulatory separation between wellness optimization and therapy.

Regulatory and Investment Considerations

The FDA does not yet recognize aging as a disease, but momentum is building. The TAME trial established precedent for treating aging as a modifiable biological process by targeting multiple chronic diseases simultaneously. Similar efforts, including GLP-1–based trials, signal growing pharmaceutical engagement. Surrogate biomarkers such as epigenetic clocks offer regulatory pathways that avoid decades-long lifespan studies.

Translation timelines are uneven but increasingly legible. Between 2025 and 2030, repurposed drugs, epigenetic diagnostics, and employer-funded genomic platforms expand at scale. Between 2030 and 2035, purpose-built longevity therapeutics and partial reprogramming advance through late-stage trials. Beyond 2035, integrated multi-omic platforms enable continuous monitoring and AI-guided intervention, including adaptation to extreme environments.

Strategic Takeaway

Enhanced Humanity is where genomics becomes personal, persistent, and proactive. The most valuable companies will not be single-product breakthroughs, but platforms integrating biology, data, incentives, and continuous intervention. For institutional investors, this category represents a fundamental shift from reactive disease treatment to proactive healthspan optimization.

Enhanced Humanity is one of GMG’s core categories because it captures the long arc of the Genomics Economy: using DNA not just to survive, but to expand human potential—on Earth, and eventually beyond it.

Top Sources & Further Reading

Longevity and Aging Biology
Nature Reviews Molecular Cell Biology
https://www.nature.com/articles/s41580-021-00386-7

Epigenetic Clocks & Biological Age
Nature Aging
https://www.nature.com/articles/s43587-021-00044-8

Partial Cellular Reprogramming
Nature
https://www.nature.com/articles/s41586-020-2975-4

Senescence & Aging Interventions
Cell
https://www.cell.com/cell/fulltext/S0092-8674(20)30773-8

Polygenic Risk Scores
Nature Medicine
https://www.nature.com/articles/s41591-021-01571-4

Microbiome & Human Health
Nature Reviews Microbiology
https://www.nature.com/articles/s41579-020-00415-8

AI in Precision & Longevity Health
The Lancet Digital Health
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(21)00265-4

TAME Trial & Metformin as Gerotherapeutic
Cell Metabolism
https://pmc.ncbi.nlm.nih.gov/articles/PMC5943638/

FDA-Approved Gerotherapeutics
Nature Aging / Clinical Studies
Evidence for SGLT2 inhibitors, metformin, bisphosphonates, and GLP-1 agonists

Space Genomics & Extreme Environment Adaptation
Nature PMC / NASA Publications
https://pmc.ncbi.nlm.nih.gov/articles/PMC10940193/

Global Anti-Aging Market Forecast
Fortune Business Insights / Allied Market Research
https://www.fortunebusinessinsights.com/anti-aging-market-103663